[go: up one dir, main page]

MA31913B1 - Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations - Google Patents

Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations

Info

Publication number
MA31913B1
MA31913B1 MA32913A MA32913A MA31913B1 MA 31913 B1 MA31913 B1 MA 31913B1 MA 32913 A MA32913 A MA 32913A MA 32913 A MA32913 A MA 32913A MA 31913 B1 MA31913 B1 MA 31913B1
Authority
MA
Morocco
Prior art keywords
hyaluronic acid
compositions containing
drug compositions
bradykinin
containing bradykinin
Prior art date
Application number
MA32913A
Other languages
Arabic (ar)
English (en)
Inventor
Carlo Alberto Maggi
Sandro Giuliani
Laura Quartara
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of MA31913B1 publication Critical patent/MA31913B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention porte sur des compositions pharmaceutiques contenant, en tant qu'ingrédients actifs, un mélange d'un polymère d'acide hyaluronique avec un antagoniste des récepteurs de la bradykinine B2. Lesdites compositions se sont révélées être particulièrement efficaces dans le traitement de maladies dégénératives des articulations, telles que l'ostéoarthrite, à l'aide d'injections intra-articulaires.
MA32913A 2007-11-23 2010-06-15 Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations MA31913B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002225A ITMI20072225A1 (it) 2007-11-23 2007-11-23 "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
PCT/EP2008/009451 WO2009065507A2 (fr) 2007-11-23 2008-11-10 Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations

Publications (1)

Publication Number Publication Date
MA31913B1 true MA31913B1 (fr) 2010-12-01

Family

ID=40314753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32913A MA31913B1 (fr) 2007-11-23 2010-06-15 Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations

Country Status (40)

Country Link
US (1) US9101627B2 (fr)
EP (1) EP2222275B1 (fr)
JP (1) JP5383695B2 (fr)
KR (1) KR101585868B1 (fr)
CN (1) CN101868225B (fr)
AP (1) AP2628A (fr)
AR (1) AR069407A1 (fr)
AT (1) ATE529096T1 (fr)
AU (1) AU2008328311B2 (fr)
BR (1) BRPI0820402A2 (fr)
CA (1) CA2706398C (fr)
CL (1) CL2008003475A1 (fr)
CO (1) CO6270301A2 (fr)
CR (1) CR11457A (fr)
CY (1) CY1112134T1 (fr)
DK (1) DK2222275T3 (fr)
EA (1) EA017626B1 (fr)
EC (1) ECSP10010153A (fr)
ES (1) ES2374861T3 (fr)
GE (1) GEP20125602B (fr)
HN (1) HN2010001037A (fr)
HR (1) HRP20110904T1 (fr)
IL (1) IL205860A (fr)
IT (1) ITMI20072225A1 (fr)
MA (1) MA31913B1 (fr)
MX (1) MX2010005484A (fr)
MY (1) MY148685A (fr)
NI (1) NI201000087A (fr)
NZ (1) NZ585514A (fr)
PA (1) PA8804801A1 (fr)
PE (1) PE20091422A1 (fr)
PL (1) PL2222275T3 (fr)
PT (1) PT2222275E (fr)
RS (1) RS52045B (fr)
SI (1) SI2222275T1 (fr)
TN (1) TN2010000215A1 (fr)
TW (1) TWI448292B (fr)
UA (1) UA97867C2 (fr)
WO (1) WO2009065507A2 (fr)
ZA (1) ZA201003586B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO131947A2 (ro) * 2014-05-30 2017-06-30 Nataliia Mykolaivna Derkach Soluţie stabilizată bazată pe substanţe active, şi metodă de preparare a soluţiei stabilizate de substanţe active
WO2016104705A1 (fr) * 2014-12-26 2016-06-30 生化学工業株式会社 Agent et procédé permettant d'améliorer des symptômes oculaires subjectifs
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
AU2021320569B2 (en) 2020-08-07 2024-10-03 Alteogen, Inc Method for producing recombinant hyaluronidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"

Also Published As

Publication number Publication date
NI201000087A (es) 2011-07-18
HN2010001037A (es) 2012-12-10
PT2222275E (pt) 2012-01-16
EA201000678A1 (ru) 2010-12-30
IL205860A (en) 2013-01-31
CY1112134T1 (el) 2015-11-04
WO2009065507A2 (fr) 2009-05-28
EP2222275A2 (fr) 2010-09-01
AU2008328311B2 (en) 2013-02-28
MY148685A (en) 2013-05-31
AR069407A1 (es) 2010-01-20
PA8804801A1 (es) 2009-06-23
AU2008328311A1 (en) 2009-05-28
US20100292156A1 (en) 2010-11-18
ZA201003586B (en) 2011-08-31
CL2008003475A1 (es) 2009-03-27
AP2010005265A0 (en) 2010-06-30
HRP20110904T1 (hr) 2011-12-31
KR101585868B1 (ko) 2016-01-22
UA97867C2 (ru) 2012-03-26
ECSP10010153A (es) 2010-06-29
PL2222275T3 (pl) 2012-03-30
WO2009065507A3 (fr) 2009-09-03
TN2010000215A1 (en) 2011-11-11
CN101868225A (zh) 2010-10-20
EP2222275B1 (fr) 2011-10-19
CN101868225B (zh) 2013-06-12
RS52045B (sr) 2012-04-30
TWI448292B (zh) 2014-08-11
HK1149714A1 (en) 2011-10-14
ITMI20072225A1 (it) 2009-05-24
IL205860A0 (en) 2010-11-30
ES2374861T3 (es) 2012-02-22
TW200927151A (en) 2009-07-01
US9101627B2 (en) 2015-08-11
EA017626B1 (ru) 2013-01-30
ATE529096T1 (de) 2011-11-15
KR20100096106A (ko) 2010-09-01
JP2011504473A (ja) 2011-02-10
DK2222275T3 (da) 2012-01-02
CR11457A (es) 2010-11-05
PE20091422A1 (es) 2009-10-17
JP5383695B2 (ja) 2014-01-08
BRPI0820402A2 (pt) 2015-05-19
AP2628A (en) 2013-03-26
NZ585514A (en) 2012-01-12
MX2010005484A (es) 2010-06-07
CO6270301A2 (es) 2011-04-20
SI2222275T1 (sl) 2012-01-31
CA2706398C (fr) 2016-07-05
CA2706398A1 (fr) 2009-05-28
GEP20125602B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA33292B1 (fr) Production de nanoparticules encapsulees a des fins commerciales
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
MA31913B1 (fr) Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA35070B1 (fr) Traitements ophtalmiques
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
MA44206A (fr) Comprimé orodispersible comprenant estetrol
EP1624874A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA35567B1 (fr) Nouvelle formulation de méloxicam
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
TNSN07343A1 (fr) Compositions ophtalmologiques et leur mode d'utilisation
MA31457B1 (fr) N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides
MA45972B1 (fr) Unité posologique orodispersible contenant un composant d'estétrol
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
AR060784A1 (es) Mezclas binarias de acido hialuronico y su uso terapeutico
MA34296B1 (fr) Composition retard injectable antipsychotique
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico
MA32635B1 (fr) Produit medicamenteux et traitement associe
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
WO2009019307A3 (fr) Compositions à base de calcitonine orale et leurs applications